Martin H. Huber's most recent trade in Syndax Pharmaceuticals Inc was a trade of 5,000 Common Stock done at an average price of $9.0 . Disclosure was reported to the exchange on May 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Martin H. Huber | Director | Purchase of securities on an exchange or from another person at price $ 8.99 per share. | 19 May 2025 | 5,000 | 79,000 (0%) | 0% | 9.0 | 44,950 | Common Stock |
| Syndax Pharmaceuticals Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 25,000 | 74,000 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 816,300 | 816,300 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 181,400 | 181,400 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 11,062 | 127,389 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 11,062 | 33,188 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Jan 2025 | 4,514 | 122,875 (0%) | 0% | 0.6 | 2,618 | Common Stock |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 166,750 | 166,750 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 166,750 | 500,250 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 1.76 per share. | 11 Sep 2024 | 50,423 | 116,327 (0%) | 0% | 1.8 | 88,744 | Common Stock |
| Syndax Pharmaceuticals Inc | Huber H. Martin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 17,000 | 49,000 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | H. Huber Martin | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 199,125 | 199,125 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 44,250 | 44,250 | - | - | Restricted Stock Unit | |
| Xilio Therapeutics Inc | Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 136,500 | 136,500 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 4,477 | 4,477 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 18,355 | 18,355 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 14,467 | 14,467 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,375 | 3,375 | - | - | Stock Option (right to buy) | |
| Syndax Pharmaceuticals Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 16,000 | 32,000 (0%) | 0% | 0 | Common Stock | |
| Xilio Therapeutics Inc | Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 136,500 | 136,500 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Martin H. Huber | PRESIDENT OF R&D AND CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Syndax Pharmaceuticals Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 16,000 | 16,000 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,185 | 10,185 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Martin H. Huber | President of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 157,058 | 157,058 | - | - | Stock Option (right to buy) | |
| Syndax Pharmaceuticals Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2021 | 35,000 | 35,000 | - | - | Stock Options (Right to buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 25,050 | 25,050 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Martin H. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 2,490 | 2,490 | - | - | Stock Option (right to buy) |